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ABSTRACT
Background and Aims It has been suggested that distributing naloxone to people who inject drugs (PWID) will lead to
fewer attendances by emergency medical services at opioid-related overdose incidents if peer administration of naloxone
was perceived to have resuscitated the overdose victim successfully. This study evaluated the impact of a national naloxone
programme (NNP) on ambulance attendance at opioid-related overdose incidents throughout Scotland. Speciﬁcally, we
aimed to answer the following research questions: is there evidence of an association between ambulance call-outs to
opioid-related overdose incidents and the cumulative number of ‘take-home naloxone’ (THN) kits in issue; and is there
evidence of an association between ambulance call-outs to opioid-related overdose incidents in early adopter (pilot) or later
adopting (non-pilot) regions and the cumulative number of THN kits issued in those areas? Design Controlled time–
series analysis. Setting Scotland, UK, 2008–15. Participants Pre-NNP implementation period for the evaluation
was deﬁned as 1 April 2008 to 31 March 2011 and the post-implementation period as 1 April 2011 to 31 March
2015. In total, 3721 ambulance attendances at opioid-related overdose were recorded for the pre-NNP implementation
period across 158 weeks (mean 23.6 attendances per week) and 5258 attendances across 212 weeks in the post-
implementation period (mean 24.8 attendances per week). Intervention Scotland’s NNP; formally implemented on
1 April 2011. Measurements Primary outcome measure was weekly incidence (counts) of call-outs to opioid-related
overdoses at national and regional Health Board level. Data were acquired from the Scottish Ambulance Service (SAS).
Models were adjusted for opioid replacement therapy using data acquired from the Information Services Division on
monthly sums of all dispensed methadone and buprenorphine in the study period. Models were adjusted further for a con-
trol group: weekly incidence (counts) of call-outs to heroin-related overdose in the London Borough area acquired from the
London Ambulance Service. Findings There was no signiﬁcant association between SAS call-outs to opioid-related over-
dose incidents and THN kits in issue for Scotland as a whole (coefﬁcient 0.009, 95% conﬁdence intervals = 0.01, 0.03,
P = 0.39). In addition, the magnitude of association between THN kits and SAS call-outs did not differ signiﬁcantly
between pilot and non-pilot regions (interaction test, P = 0.62). Conclusions The supply of take-home naloxone kits
through aNational Naloxone Programme in Scotlandwas not associated clearly with a decrease in ambulance attendance
at opioid-related overdose incidents in the 4-year period after it was implemented in April 2011.
Keywords Ambulance, controlled time–series, evaluation, naloxone, opioid, overdose.
Correspondence to: Andrew McAuley, Health Protection Scotland, Meridian Court, Glasgow G2 6QE, UK. E-mail: andrew.mcauley@nhs.net
Submitted 15 March 2016; initial review completed 6 June 2016; ﬁnal version accepted 8 September 2016
INTRODUCTION
Drug-related death (DRD) is a global public health issue
and a major cause of premature mortality among people
who inject drugs (PWID) [1]. Opioid misuse is of particular
concern and accounts for an estimated 69000 deaths
world-wide each year [2]. DRD rates in Scotland are higher
than in any other UK region and are among the highest in
Europe [3].
Since ﬁrst proposed in 1996 [4], the distribution of the
opioid antagonist naloxone for lay administration [hence-
forth, ‘take-home naloxone (THN)’] has emerged as a key
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component of DRD prevention strategies internationally.
Guidelines published by the World Health Organization
(WHO) in 2014 [2] recommended expansion of naloxone
access to people likely to witness an overdose in their com-
munity, and it is now supplied to PWID and their
family/friends in an increasing number of countries. In
the United States, it is estimated that more than 26000
peer-administered naloxone reversals (i.e. where naloxone
was used to ‘reverse’ an opioid-related overdose) were
achieved between 1996 and 2014 [5]. Following success-
ful pilots in three regions of Scotland, the Scottish
Government established a national naloxone programme
(NNP) in 2010 aimed at reducing DRD rates: the ﬁrst of
its kind anywhere in the world [6].
Using interrupted time–series analysis, Walley et al. [7]
compared communities in Massachusetts (USA) with high
and low rates of THN implementation to those with no im-
plementation and found evidence of a dose-related impact
where higher cumulative rates of implementation were as-
sociatedwith greater reductions in death rates. Since its in-
ception, the NNP in Scotland has distributed more than
20000 THN kits, which have been associated with a
36% reduction in opioid-related deaths during the 4 weeks
following prison release [8].
Despite such successes, the supply of THN remains con-
troversial, as it is thought that it may increase risky behav-
ior, e.g. by encouraging PWID to consume greater volumes
of drugs in the knowledge that they have a ‘safety net’. One
additional concern is that availability of THN would lead to
fewer calls to the emergency medical services if it appeared
to have resuscitated the overdose victim successfully [9].
Indeed, it has been suggested that distributing THN to
PWID will lead to a perception that it is a ‘magic bullet’
and is all that is required to reverse an overdose, negating
the need for any attendance by the emergency medical
services [10].
These reported concerns are not without foundation.
Just fewer than two-thirds (62%) of PWIDs surveyed in
San Francisco reported that they would be less likely to call
emergency services if they had access to naloxone [11].
Homeless drug users in the United Kingdom have also inti-
mated that they would see THN as an appropriate substi-
tute to calling an ambulance at an overdose event [12].
In such a scenario, THN has the potential to create an
additional barrier to PWID accessing help from profes-
sional health-care providers if they perceive that they can
self-manage any opioid overdose they encounter. This is
problematic, given that naloxone is short-acting and that
the patient may revert into a state of overdose [13,14].
In observational studies of THN which recorded ambu-
lance call-outs to overdose incidents at follow-up atten-
dance ranged from 29 to 100%; two-thirds of studies
reported ﬁgures of fewer than 50% [14]. Attendance by
emergency medical personnel is perceived negatively by
PWID due mainly to its association with police attendance
[15–17]. Ambulance attendance reduces potential for re-
bound toxicity and provides access to professional emer-
gency care, which those suffering an opioid-related
overdose require. As well as provision of immediate clinical
assessment and care, ambulance attendance at the scene
of an overdose offers potential for distribution of THN to
those who have been unable to access it through existing
supply routes [18] or those seeking re-supply of already
used kits.
Evidence for the unintended consequences of THN is
currently limited. In particular, studies of the impact of
naloxone supply among PWID at a population level are
lacking. To address this key gap in the THN literature, this
population-level ecological study aimed to evaluate the im-
pact of a NNP on ambulance attendance at overdose.
Speciﬁcally, we aimed to answer the following research
questions:
1 Is there evidence of an association between ambulance
call-outs to opioid-related overdose incidents and the
cumulative number of THN kits in issue as adjusted
for opioid replacement therapy (ORT) and a control
group?
2 Is there evidence of an association between ambulance
call-outs to opioid-related overdose incidents in early
adopter (pilot) areas and the cumulative number of
THN kits issued in those areas as adjusted for ORT and
a control group?
3 Is there evidence of an association between ambulance
call-outs to opioid-related overdose incidents in later
adopting (non-pilot) areas and the cumulative number
of THN kits issued in those areas as adjusted for ORT
and a control group?
The current study is timely, given the increasing adop-
tion of THN internationally, the importance of ambulance
attendance at opioid-related overdose and uncertainty
about the effect of THN on such attendance.
METHODS
Setting
This study was conducted in Scotland, UK, 2008–15.
Intervention
The number of THN kits were supplied through Scotland’s
NNP, formally implemented on 1 April 2011. In Scotland,
THN is supplied following a brief 5–10-minute training ses-
sion, mainly via community addiction treatment and harm
reduction services, and to at-risk prisoners on release.
Training sessions typically cover signs and symptoms of
opioid overdose, basic life support, naloxone administration
and calling an ambulance.
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Observations
The pre-NNP implementation period for the evaluation
was deﬁned as 1 April 2008 to 31 March 2011 and the
post-implementation period as 1 April 2011 to 31 March
2015. In total, 3721 ambulance attendances at opioid-
related overdose were recorded for the pre-NNP implemen-
tation period across 158 weeks (mean 23.6 attendances
per week) and 5258 attendances across 212 weeks in the
post-implementation period (mean 24.8 attendances per
week).
Primary outcome measure




Time–series analysis was undertaken for the period 1 April
2008 to 31 March 2015 using weekly call-outs to opioid-
related overdose by the SAS as the dependent variable
and cumulative number of THN kits issued as part of the
NNPas the explanatory variable. Pre-NNP implementation
period for the evaluation was deﬁned as 1 April 2008 to 31
March 2011 and the post-implementation period as 1
April 2011 to 31 March 2015. Roll-out of the programme
was not uniform across the country from 1 April 2011 (see
Appendix S1), therefore we used the number of cumulative
kits in issue as a continuous covariate within the model
rather than a single date of implementation. Analysis was
adjusted for ORT, and London ambulance call-outs to her-
oin overdoses were included as a control. Supplementary
analysis was undertaken to explore whether effects varied
between early adopters (i.e. the three pilot regions) and
those engaging with the programme at a later date. All
analysis was pre-speciﬁed in an analysis plan.
Data
Anonymized data were obtained on all weekly THN sup-
plies provided for lay administration in Scotland through
the NNP between 2011 and 2015. Given the focus of the
study on lay administration, only supplies made to those
at risk of opioid overdose and their family/friends were in-
cluded; supplies made to service staff were excluded. Data
on THN kits supplied were provided by the Information
Services Division of the National Health Service Scotland
at both national and regional levels. Data on THN kits sup-
plied in Scotland before this period (e.g. within the three
early adopting regions during their pilot phase) were not
included within the study due to inconsistencies in data
collection methods across the three regions.
Anonymized data were also requested on all ambu-
lance attendances at opioid-related overdose incidents
between 2008 and 2015. Data were drawn from the ﬁ-
nal Advanced Medical Priority Dispatch System codes
input by the ambulance crew who had seen the patient
face-to-face. Based on advice from SAS colleagues, we
included incidents where diagnostic code 23C05 [Over-
dose/Poisoning, Narcotics (Heroin)] was used or where
diagnostic code group 23 (Overdose/Poisoning) was used
and the additional factor ‘opiate’ was noted by the crew.
Data were again supplied on a weekly basis at both
national and regional levels. SAS attendance data are
limited in terms of details which would allow analysis
of subgroups. The only additional data available beyond
the date of the incident and type of overdose involved
were postcodes (four-digit). In light of these data
limitations we elected to explore potential differential
impacts by regional area only within supplementary
analysis.
Despite establishing contact with representatives from
other administrations, no suitable control area was identi-
ﬁed. This was either as a result of absence of data (England,
Ireland, Northern Ireland) or because of the existence of
another NNP (Wales). During this scoping exercise we
identiﬁed ambulance attendance data for the London
Borough area, speciﬁcally London Ambulance Service
(LAS) attendance at ‘heroin-related’ overdose. As in
Scotland, LAS datawere also drawn from the dispatch code
for overdose, but speciﬁcally for cases where ‘heroin’ was
noted. As well as being based on the term ‘heroin’ only,
these data differed from those provided by SAS in that they
were derived from the system used by the call-handlers
within the ambulance control centre (not the ‘ﬁnal’ dis-
patch code sourced from the ambulance crewclinical notes
as used within the SAS data). No other data on opioid-
related overdose were available from LAS.
Potential confounding variables were considered and
decided upon based on evaluating the existing literature
and availability of data. To be included, confounders
had to link plausibly to both the outcome and exposure
and be time-variant (i.e. weekly or monthly). For exam-
ple, ORT was included given the established evidence
that drug treatment is protective against overdose [19]
and also that treatment services are one of the main ve-
hicles in the community for supplying THN within the
NNP. Therefore, anonymized data on the total sum of
all prescribed quantities [dispensed in milligrams (mg)]
of methadone and buprenorphine between 2008 and
2015 were sourced from the Information Services Divi-
sion, this time on a monthly basis (weekly not available)
at national and regional levels. Both ORT measures were
included separately because it was not possible to com-
bine them into a single meaningful measure due to dose
discrepancy.
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Statistical analysis
SAS call-out counts for opioid-related overdoses are time–
series data and likely to be autocorrelated, therefore stan-
dard regression techniques are unsuitable. One approach
to modelling time–series data is to use regression models
with autoregressive integrated moving average (ARIMA)
errors. The ﬁrst step in the modelling strategy was to in-
spect autocorrelation and partial autocorrelation plots of
the dependent variable (i.e. the weekly ambulance call-
out counts) in order to determine the underlying error
structure of the models [20]. Error terms were added to re-
duce autocorrelation then removed systematically to ﬁnd
the most parsimonious model. The preferred model was
then subjected to standard diagnostic tests including
checking for autoregressive conditional heteroscedasticity
(ARCH effects) [21] by comparing standard errors pro-
duced with and without the robust option and checking
that residuals contained no remaining autocorrelation.
The explanatory variable (cumulative THN kits) was then
added to this initial model before testing the effect of the ad-
ditional covariates (ORT—methadone and buprenorphine)
and the LAS call-out data [22]. The SAS call-out datawere
log-transformed to stabilize the variance in the series.
Goodness-of-ﬁt is reported as R2 between observed and
ﬁtted models. The Bayes factor was calculated for the
results of the main analysis [23]. To test whether the effect
size was different in the pilot compared to the non-pilot
regions, an interaction term between a variable indicating
pilot/non-pilot and the cumulative THN kits was added to
the modelling [linear regression with lag terms identiﬁed
by the time–series modelling was used for this purpose as
data were no longer a single time–series with two observa-
tions per time-point (from pilot and non-pilot regions)].
All analyses were undertaken using Stata/SE 14 soft-
ware (Stata Corp, College Station, TX, USA, 2015). Graphs
were produced in R version 3.2.0 (R Development Core
team, Vienna, Austria, 2008). Ethical approval was not
required for this study.
RESULTS
Descriptive analysis
Figure 1 shows crude trends in weekly incidence of SAS
call-outs to opioid-related overdoses. Figure 2 shows crude
trends in weekly supplies of THN, LAS call-outs to heroin-
related overdoses and monthly ORT prescription data
(methadone and buprenorphine). The implementation
date when THN kits began to be made available to PWID
is marked by a vertical line on each ﬁgure at 1 April 2011.
Visual inspection of the data shows that opioid-related
SAS call-outs did not appear to reduce after THN kits
started to be issued (Fig. 1). The mean weekly number of
SAS call-outs to opioid-related overdose over the period of
the study increased from 23.6 in the pre-NNP era
(2008–11) to 24.8 in the 4-year period following imple-
mentation (2011–15). Seasonal variation is evident with
summer peaks visible across the majority of the
time–series. LAS call-outs to heroin-related overdoses also
appeared to increase in the post-April 2011 period with
the mean weekly number increasing from 2.9 (2008–11)
to 5.1 (2011–15) across the time–series (Fig. 2).
For ORT, methadone prescriptions were on an
increasing trend between 2008 and 2011, but appeared
to peak around April 2011 then reduce thereafter. In con-
trast, buprenorphine prescriptions increased steadily over
the period under review.
Statistical analysis
Main model
There was no evidence that the number of THN kits in
issue was associated with a difference in SAS call-outs to
Figure 1 Weekly call-outs to opioid-related overdose (Scottish Ambulance Service), 2008–15 [1]
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opioid-related overdoses. For Scotland as a whole, the coef-
ﬁcient relating to each of the 1000 THN kits in issue
(adjusted for ORT and London ambulance control) was
0.009 [95% conﬁdence interval (CI) = 0.01 to 0.03,
P = 0.39] (Table 1). The Bayes factor was calculated as
9.58, which can be interpreted to mean that the null
hypothesis (i.e. that THN was not associated with SAS
call-outs) is almost 10 times more likely to be true than
the alternative hypothesis (i.e. that THN was associated
with SAS call-outs).
Supplementary analysis
In the three early adopter (pilot) regions there was no evi-
dence that the number of THN kits in issue was associated
with weekly SAS call-outs (coefﬁcient 0.059, 95%
CI = 0.03 to 0.16, P = 0.22) (Table 1). In the later
adopting (non-pilot) regions there was no evidence that
the number of THN kits in issue was associated with a dif-
ference in weekly SAS call-outs (coefﬁcient  0.024, 95%
CI =0.08 to 0.04, P = 0.42) (Table 1). The P-value from
the interaction test was 0.62, indicating no evidence of a
different magnitude of association between THN kits and
SAS call-outs in pilot and non-pilot regions.
DISCUSSION
Contrary to prior speculation in the literature, our results
show that supply of THN through an NNP in Scotland
has not been associated with a decrease in ambulance at-
tendance at opioid-related overdose incidents in the 4-year
period after it was introduced. These ﬁndings were
consistent in both national level analysis and when





95 % CIs P-value R-squared
Lower Upper %
All areas Unadjusted 0.001 0.006 0.00 0.02 0.23 27.4
Adjusted for ORT 0.001 0.011 0.01 0.03 0.29 28.1
Adjusted for ORT with
London control
0.009 0.011 0.01 0.03 0.39 28.3
Pilot areas Unadjusted 0.043 0.034 0.02 0.11 0.20 18.9
Adjusted for ORT 0.053 0.047 0.04 0.15 0.26 19.4
Adjusted for ORT with
London control
0.059 0.047 0.03 0.16 0.22 19.6
Non-pilot areas Unadjusted 0.010 0.016 0.02 0.04 0.51 18.2
Adjusted for ORT 0.020 0.030 0.07 0.04 0.50 19.1
Adjusted for ORT with
London control
0.024 0.030 0.08 0.04 0.42 19.3
SE = standard error; CI = conﬁdence interval; ORT = opioid replacement therapy.
Figure 2 Weekly call-outs to heroin-related overdose (London Ambulance Service), 2008–15; weekly supplies of take-home naloxone (THN)
made via the Scottish national naloxone programme (NNP), by setting, 2008–15; monthly prescribed quantities of methadone (dispensed in mg),
Scotland, 2008–15; monthly prescribed quantities of buprenorphine (dispensed in mg), Scotland, 2008–15
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exploring differences between early adopting regions and
those areas implementing THN at a later date.
The main strengths of this study are in its novel use of
routine data to explore potential unintended consequences
associated with a NNP through controlled time–series
analysis. Scotland is one of only two countries currently
with a NNP (Wales being the other) and beneﬁts from ac-
cess to large national data sets collected consistently over
the periods before and after implementation, thus facilitat-
ing a study of this kind. The length of the time–series is
particularly important in countering spurious trends asso-
ciated with overdoses occurring in clusters [7].
Despite these study strengths, the process for identify-
ing accurately all ambulance attendances at opioid-related
overdose incidents was challenging, and is prone to under-
estimation. Indeed, the differences in magnitude between
SAS and LAS weekly call-outs are probably explained by
the different data recording and coding procedures oper-
ated between the two services. However, by using the ﬁnal
dispatch code recorded by the SAS crew themselves, the
risk of misintepretation or missing data is minimized in
the main model and provides us with the best means to as-
sess patterns in attendance accurately over time. Seasonal
trends evidentwithin the descriptive analysis validate these
data further, notably the peaks in SAS attendance at
opioid-related overdose in the summer months, which are
consistent with previous studies [24,25]. The summer
peaks are less evident in 2011 and 2012, which we ascribe
to the European heroin drought during that period [26,27]
and the association between heroin droughts and reduc-
tions in rates of overdose [28,29].
The threat of unmeasured confounding is particularly
acute for natural experimental studies [30]. Where genu-
ine alternative explanations for an observed effect rather
than the intervention exist, internal validity may be com-
promised. Importantly, SAS clinical guidelines for naloxone
use had not changed during the study period and were
therefore unlikely to have inﬂuenced practice. The poten-
tial for alternative explanations to changes in SAS atten-
dance at opioid-related overdose was addressed by
consideration of a range of confounding variables. Al-
thoughwe included one confounder (i.e. ORT), others were
excluded; speciﬁcally, heroin purity levels and the prison
population. The former was rejected due to limited avail-
ability of relevant data and inconclusive evidence associat-
ing heroin purity levels with overdose rates [31]. The latter
is linked more strongly to the outcome, given the high
prevalence of illicit drug use on admission to prison, the
use of prisons as a vehicle for THN supply in Scotland
alongside community services and the heightened risk of
overdose on release [32]. An additional factor here is the
high volume of prisoners serving short-term sentences for
drug and drug-related offences, which increases the inci-
dent number of transient risk periods for drug-related
harms (i.e. overdose) experienced by this marginalized co-
hort. However, it is important to recognize that prisoners-
on-release can beneﬁt from THN kits issued from the prison
estate as well as from the community, and vice versa [33].
Despite these theoretical links, time–series data on prison
admissions and/or liberations were unavailable, thus the
potential for residual and temporal confounding remains.
Finally, we acknowledge that a potential increase (or de-
crease) in opioid-related deaths might have had an impact
upon ambulance attendance at opioid-related overdose.
However, national statistics reveal that the crude number
of opioid-related deaths did not change signiﬁcantly during
the study period, averaging 424 in the pre-NNP era
(2008–10) and 415 post-NNP implementation
(2011–14) [34].
Our study would have beneﬁted from comparison with
a national ‘control’ area using similar data collection
methods. However, insufﬁcient datawere available to prog-
ress such an approach. As an alternative we included data
on heroin-related overdoses attended by LAS. This is likely
to be a weak control due to the differences in data collec-
tion cited in our Methods section. Moreover, we were un-
able to source any available relevant data which could be
used to compare the opioid markets directly (e.g. ORT pre-
scribing data) in Scotland and London Borough. This limits
further the effectiveness of LAS data as a control for opioid-
related overdoses attended by SAS.
There are no speciﬁc studies, to date, which have evalu-
ated the impact of naloxone programmes on ambulance at-
tendance at overdose incidents. Our study provides the ﬁrst
empirical evidence in response to conjecture that provision
of THN would lead to fewer ambulances attending opioid-
related overdoses. Our results provide no evidence of such
a relationship in Scotland. In reviewing the literature, we
identiﬁed one previous studywhich investigated the impact
of another key drug policy (Supervised Injecting Facility) on
ambulance call-outs to overdose [35]. The authors found
that the ambulance service attended signiﬁcantly fewer
opioid-related overdoses in the area surrounding the facility
after it began operating when compared to the rest of the
state of New South Wales, Australia. The effect was partic-
ularly strong during opening hours and in the immediate
area surrounding the facility.
This study adds considerably to the evidence base in
this ﬁeld by shedding light upon one measurable example
of a range of potential behavioural changes that might
have occurred among those supplied with THN, and sug-
gests that THN kits in issue are not associated with ambu-
lance attendance at opioid-related overdose incidents.
Although it is encouraging that ambulance attendance
has not decreased since the introduction of NNP, nor has
it increased to any substantial degree. Calling an ambu-
lance is a core component of the Scottish NNP training
model alongside overdose identiﬁcation, basic life support
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and naloxone administration. Opioid overdose is an acute
medical condition which requires specialist intervention
and support, therefore these ﬁndings should be used as a
catalyst for policy and practice to reinforce the importance
of calling an ambulance at all future incidents. Speciﬁcally,
education and health promotion centred on calling an am-
bulance should be an essential element of any THN pro-
gramme internationally.
As the ﬁrst study of its kind, the generalizability of its
ﬁndings is limited. Future research should consider the ap-
plicability of these ﬁndings over a longer time–series and in
other territories to determine whether ambulance atten-
dance at overdose events is inﬂuenced by THN in different
ways across different populations. Comparison between pi-
lot and non-pilot regions merit further exploration, in par-
ticular to determine if patterns of ambulance attendance at
opioid-related overdose vary over time between early
adopters and those implementing THN at a later date.
CONCLUSIONS
Our study found no evidence that the number of THN kits
in issue is associated with a difference in ambulance atten-
dance at opioid-related overdose. This study provides obser-
vational evidence to refute claims that availability of
naloxone decreases incidence of ambulance attendance at
overdose. Future research should consider the applicability
of these ﬁndings in other territories and whether the rela-
tionship between naloxone supply and ambulance atten-
dance at overdose is sustained in the long term.
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